Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03250585 · ClinicalTrials.gov registry record
sPLA2 in EBC During Acute Chest Syndrome
A clinical trial, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- 6
- Enrollment target
NCT03250585: Completed study, sponsored by Virginia Commonwealth University.
NCT03250585 is a clinical trial that has completed, run by Virginia Commonwealth University. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03250585 has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- 6 participants
- Enrollment target
Study Summary
Secretory phosholipases A2 (sPLA2) are significantly elevated in the plasma of sickle cell disease patients with acute chest syndrome (ACS), and similar enzymes have been measured in exhaled breath condensate (EBC), which is collected easily and non-invasively. The investigators hypothesize that sPLA2 will be measurable in EBC samples from sickle cell patients with acute chest syndrome.
Primary Outcome
sPLA2 level in EBC at Time point 1 (during acute ACS episode) as measured by ELISA
Interventions
- DIAGNOSTIC_TEST Exhaled Breath Condensate (EBC)
- DIAGNOSTIC_TEST Plasma Sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-01-19 |
| Est. Completion | 2018-06-14 |
What the finished NCT03250585 record still lists
NCT03250585 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Exhaled Breath Condensate (EBC) is the first listed.
NCT03250585 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03250585 about?
NCT03250585 is a clinical study titled "sPLA2 in EBC During Acute Chest Syndrome". Secretory phosholipases A2 (sPLA2) are significantly elevated in the plasma of sickle cell disease patients with acute chest syndrome (ACS), and similar enzymes have been measured in exhaled breath condensate (EBC), which is collected easily and non-invasively. The investigators hypothesize that sPL...
What is the current status of trial NCT03250585?
This trial is currently completed. The enrollment target is 6 participants. The study started on 2018-01-19. Estimated completion is 2018-06-14.
What interventions are being tested in trial NCT03250585?
The interventions under investigation include: Exhaled Breath Condensate (EBC) (DIAGNOSTIC_TEST), Plasma Sample (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03250585?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI